Iron Replacement Therapy

Introduction to Iron Replacement

• The European Crohn's and Colitis Organization recommends intravenous iron over oral iron as first-line therapy in patients with hemoglobin <10 g/dL, due to the potential for unabsorbed oral iron to cause mucosal harm and exacerbate disease activity 1, 3

Clinical Algorithm for Route Selection

• The American Gastroenterological Association suggests using intravenous iron as first-line therapy in patients with hemoglobin <10 g/dL, active inflammatory bowel disease, previous intolerance to oral iron, or conditions impairing iron absorption 1, 2
• The European Crohn's and Colitis Organization recommends oral iron for mild anemia (Hb 11-13 g/dL) in patients with clinically inactive disease and no prior oral iron intolerance 1, 3

Specific Disease Context Considerations

• In patients with inflammatory bowel disease, intravenous iron is superior to oral iron, with a meta-analysis showing an odds ratio of 1.57 for achieving a 2.0 g/dL hemoglobin increase and significantly lower treatment discontinuation rates (odds ratio 0.27) 2
• The American Society of Clinical Oncology recommends intravenous iron as the preferred treatment for cancer-related anemia due to inflammation-induced hepcidin upregulation 5

Practical Dosing Guidance

• The European Crohn's and Colitis Organization suggests that oral iron may be considered only in clinically inactive IBD with mild anemia (Hb >11 g/dL), with a maximum dose of 100 mg elemental iron per day to minimize gastrointestinal side effects 1, 6
• The American Gastroenterological Association recommends continuing oral iron for 3 months after hemoglobin normalizes to replenish iron stores 4

Critical Safety Considerations

• The European Crohn's and Colitis Organization recommends monitoring serum phosphate levels in patients requiring repeat courses of intravenous iron, as ferric carboxymaltose carries a risk of symptomatic hypophosphatemia 1
• The American Society of Clinical Oncology suggests avoiding iron dextran when possible due to a higher anaphylaxis risk requiring test doses 1

Monitoring After Treatment

• The European Crohn's and Colitis Organization recommends checking hemoglobin every 3 months for the first year after correction, then at 6-12 month intervals, and re-treating with intravenous iron when ferritin drops below 100 μg/L or hemoglobin falls below 12-13 g/dL (gender-dependent) 3